Posastiuc Florin-Petrișor, Constantin Nicolae-Tiberiu, Domain Guillaume, Spanoghe Lotte, Van Soom Ann, Diaconescu Alexandru Ilie, Codreanu Mario-Darius
Department of Internal Medicine, Reproduction and Population Medicine, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium.
Department of Clinical Sciences II, Faculty of Veterinary Medicine, University of Agronomic Sciences and Veterinary Medicine of Bucharest, 105 Blvd. Splaiul Independentei, 050097 Bucharest, Romania.
Animals (Basel). 2025 May 30;15(11):1614. doi: 10.3390/ani15111614.
Benign prostatic hyperplasia (BPH) is a common condition in intact male dogs, often progressing from subclinical to symptomatic stages with increasing clinical and structural impact. This study evaluated canine prostate-specific esterase (CPSE) as a biomarker for BPH progression, focusing on clinical severity, complexity, and ultrasonographic features. Seventy-one dogs were included: subclinical-BPH (n = 14), clinical-BPH (n = 26), BPH-prostatitis (n = 9), and controls (n = 22). CPSE levels, measured using a canine-specific enzyme-linked immunosorbent assay, were significantly correlated with clinical severity ( = 0.800, ≤ 0.001) and complexity ( = 0.818, ≤ 0.001). CPSE predicted mild (OR = 1.260, B = 0.231, ≤ 0.001) and moderate severity (OR = 1.300, B = 0.262, ≤ 0.001), as well as low (OR = 1.225, B = 0.203, ≤ 0.05), moderate (OR = 1.235, B = 0.211, ≤ 0.01), and high (OR = 1.346, B = 0.297, ≤ 0.001) clinical complexity. CPSE showed a trend toward predicting structural alterations (OR = 1.227, B = 0.204, = 0.069) and was associated with larger stippled areas, increased prostatic volume, and larger cysts/abscesses (all ≤ 0.001). CPSE appears to be a promising marker for BPH progression.
良性前列腺增生（BPH）在未绝育的雄性犬中是一种常见病症，通常会随着临床和结构影响的增加，从亚临床阶段发展到有症状阶段。本研究评估了犬前列腺特异性酯酶（CPSE）作为BPH进展的生物标志物，重点关注临床严重程度、复杂性和超声特征。纳入了71只犬：亚临床BPH组（n = 14）、临床BPH组（n = 26）、BPH-前列腺炎组（n = 9）和对照组（n = 22）。使用犬特异性酶联免疫吸附测定法测量的CPSE水平与临床严重程度（r = 0.800，P ≤ 0.001）和复杂性（r = 0.818，P ≤ 0.001）显著相关。CPSE可预测轻度（OR = 1.260，B = 0.231，P ≤ 0.001）和中度严重程度（OR = 1.300，B = 0.262，P ≤ 0.001），以及低（OR = 1.225，B = 0.203，P ≤ 0.05）、中（OR = 1.235，B = 0.211，P ≤ 0.01）和高（OR = 1.346，B = 0.297，P ≤ 0.001）临床复杂性。CPSE显示出预测结构改变的趋势（OR = 1.227，B = 0.204，P = 0.069），并且与更大的点状区域、前列腺体积增加和更大的囊肿/脓肿相关（均P ≤ 0.001）。CPSE似乎是BPH进展的一个有前景的标志物。
